KTTA Pasithea Therapeutics Corp. - Common Stock
NASDAQ · Biotechnology close Oct 2, 2026KTTA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
KTTA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| Jan. 2, 2024 | 1-for-20 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 14, 2026 | $-0.16 | $-0.16 | 2.0% |
| March 31, 2026 | May 15, 2026 | $-0.12 | $-0.46 | 73.9% |
| Dec. 31, 2025 | $-0.79 | $-0.18 | -330.3% | |
| Dec. 31, 2024 | $-2.41 | — | — | |
| March 31, 2022 | $-1.40 | $-0.41 | -243.1% | |
| Dec. 31, 2021 | $2.40 | $-1.02 | 335.3% |
Institutional owners (13F) 26 filers · $9.3M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 5 (+2 vs prior Q) | 0 (-8 vs prior Q) | 10 (+4 vs prior Q) | 4 (+1 vs prior Q) | +3.2M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $1,564,500 | 2,100,000 | 16.90% | Shares |
| Cable Car Capital, LP | $1,546,200 | 3,000,000 | 16.70% | Shares |
| Stonepine Capital Management, LLC | $1,134,637 | 2,201,468 | 12.25% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $1,082,340 | 2,100,000 | 11.69% | Shares |
| Opaleye Management Inc. | $1,056,570 | 2,050,000 | 11.41% | Shares |
| AMERIPRISE FINANCIAL INC | $960,955 | 1,864,485 | 10.38% | Shares |
| Squadron Capital Management LLC | $515,400 | 1,000,000 | 5.57% | Shares |
| AdvisorShares Investments LLC | $483,213 | 937,550 | 5.22% | Shares |
| Vivo Capital, LLC | $239,904 | 465,471 | 2.59% | Shares |
| Persistent Asset Partners Ltd | $149,752 | 290,555 | 1.62% | Shares |
| VANGUARD GROUP INC | $126,000 | 97,675 | 1.36% | Shares |
| UBS Group AG | $96,877 | 188,111 | 1.05% | Shares |
| XTX Topco Ltd | $65,751 | 127,572 | 0.71% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $65,034 | 126,279 | 0.70% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $43,221 | 83,856 | 0.47% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $33,810 | 65,600 | 0.37% | Shares |
| TWO SIGMA INVESTMENTS, LP | $33,071 | 64,166 | 0.36% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $22,588 | 43,860 | 0.24% | Shares |
| NORTHERN TRUST CORP | $16,186 | 31,405 | 0.17% | Shares |
| Jump Financial, LLC | $15,133 | 29,363 | 0.16% | Shares |
| Tower Research Capital LLC (TRC) | $4,555 | 8,838 | 0.05% | Shares |
| Hurley Capital, LLC | $3,608 | 7,000 | 0.04% | Shares |
| SBI Securities Co., Ltd. | $542 | 1,051 | 0.01% | Shares |
| BARCLAYS PLC | $139 | 269 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $79 | 150 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 275 | 0.00% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Lawrence Steinman | June 8, 2023 | · | Initial filing | · | SEC |
| Concord IP2 Ltd. (2), Elderhill Corporation (2), David Delaney (2), Leonite Capital LLC (2), Leonite Fund I, LP (2), Avi Geller (2), Camac Partners, LLC (2), Camac Capital, LLC (2), Camac Fund, LP (2), Eric Shahinian (2) ×10 filings | Jan. 10, 2023 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 8 insiders · 4 officers · 5 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Tiago Marques | Chief Executive Officer | May 1, 2026 A | 73,334 | 1 | 0 | $25,000 |
| Daniel H Schneiderman | Chief Financial Officer | May 1, 2026 A | 26,667 | 0 | 0 | $0 |
| Kartik Krishnan | Chief Medical Officer | May 1, 2026 A | · | 0 | 0 | $0 |
| Graeme Martin Currie | Chief Development Officer | March 1, 2024 A | · | 0 | 0 | $0 |
| Simon Dumesnil | Director | May 1, 2026 A | 35,833 | 1 | 0 | $25,000 |
| Emer Leahy | Director | May 1, 2026 A | 33,333 | 0 | 0 | $0 |
| Alfred J Novak | Director | May 1, 2026 A | 3,500 | 0 | 0 | $0 |
| Lawrence Steinman | Director | May 1, 2026 A | 199,691 | 1 | 0 | $100,000 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 1 ETF
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0.00% | 126,279 SH | Aug. 19, 2026 | Daily |
KTTA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-10-01Mean target $3.00 +530.3%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.